NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1
Terminated
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell Lymphoma
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00354185
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Delaying the Progression of Diabetic Nephropathy in Pima Indians
Completed
- Conditions
- Diabetic Nephropathy
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 25
- Registration Number
- NCT00353600
- Locations
- 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States
Agriculture Health Study
Active, not recruiting
- Conditions
- LymphomaProstate CancerPesticide ExposuresMultiple Myeloma
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 89655
- Registration Number
- NCT00352924
- Locations
- 🇺🇸
Research Triangle Institute, Research Triangle Park, North Carolina, United States
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Phase 1
Completed
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiableAccelerated Phase of DiseaseAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARAde Novo Myelodysplastic SyndromePrimary MyelofibrosisAdult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT00351975
- Locations
- 🇳🇿
Princess Margaret Hospital, Cashmere, Canterbury, New Zealand
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monocytic Leukemia (M5b)Adult Acute Basophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Erythroleukemia (M6a)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00352365
- Locations
- 🇺🇸
Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States
🇺🇸Great Falls Clinic, Great Falls, Montana, United States
🇺🇸Bozeman Deaconess Cancer Center, Bozeman, Montana, United States
Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan
Completed
- Conditions
- Type I Diabetes
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 30
- Registration Number
- NCT00351650
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Phase 1
Completed
- Conditions
- Stage IV MelanomaMelanomaRecurrent MelanomaStage III Melanoma
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT00349206
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Phase 1
Completed
- Conditions
- Male Breast CancerStage IV Ovarian Epithelial CancerRecurrent Breast CancerRecurrent Renal Cell CancerStage IV Breast CancerStage IV Primary Peritoneal Cavity CancerStage IV Renal Cell CancerRecurrent Ovarian Epithelial CancerUnspecified Adult Solid Tumor, Protocol SpecificRecurrent Primary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT00348699
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1
Completed
- Conditions
- Recurrent Adult Diffuse Mixed Cell LymphomaStage III Adult Burkitt LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisAngioimmunoblastic T-cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00348985
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
Genetic Susceptibility to Factor VIII Inhibitors
Completed
- Conditions
- Hemophilia
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1187
- Registration Number
- NCT00344435
- Locations
- 🇸🇪
University Hospital, University of Lund, Malmo, Sweden